Polpharma European CDMO Partner & API Manufacturer since 1951 Polpharma European CDMO Partner & API Manufacturer since 1951

X

Find Radio Compass News for Olaparib

PharmaCompass
Related ProductsRelated Products
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

EU WC

EU WC

Listed Suppliers

Listed Suppliers

API REF. PRICE (USD / KG)
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

SERVICES

0

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/dcgi-orders-withdrawal-of-cancer-drug-olaparib-for-certain-treatments/articleshow/110342492.cms

ECONOMICTIMES
23 May 2024

https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/regulator-asks-state-bodies-to-limit-scope-of-key-cancer-drug/articleshow/110312729.cms

ECONOMICTIMES
23 May 2024

https://www.biospace.com/article/tango-stops-early-cancer-trial-over-liver-toxicity-drops-out-of-race-against-roche/

BIOSPACE
23 May 2024

https://www.fiercepharma.com/pharma/aacr-detailed-data-spark-glimmer-hope-mercks-keytruda-lynparza-combo-lung-cancer

Angus Liu FIERCE PHARMA
09 Apr 2024

https://www.businesswire.com/news/home/20240321699486/en

BUSINESSWIRE
21 Mar 2024

https://www.biospace.com/article/astrazeneca-shows-lynparza-combo-could-address-unmet-endometrial-cancer-need/

BIOSPACE
19 Mar 2024

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-launches-anti-cancer-generic-drug-olaparib-in-india/articleshow/108471360.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

ECONOMIC TIMES
13 Mar 2024

https://www.businesswire.com/news/home/20231207532705/en/Merck-Announces-KEYLYNK-008-Trial-Evaluating-KEYTRUDA%C2%AE-pembrolizumab-Plus-LYNPARZA%C2%AE-olaparib-for-Patients-With-Metastatic-Squamous-Non-Small-Cell-Lung-Cancer-to-Stop-for-Futility

BUSINESSWIRE
08 Dec 2023

https://www.businesswire.com/news/home/20231021558683/en

BUSINESSWIRE
21 Oct 2023

https://www.businesswire.com/news/home/20230824404671/en

BUSINESSWIRE
24 Aug 2023

https://www.biospace.com/article/releases/health-canada-approves-lynparza-in-combination-with-abiraterone-and-prednisone-or-prednisolone-for-patients-with-brca-mutated-metastatic-castration-resistant-prostate-cancer/

BIOSPACE
14 Jul 2023

https://www.onclive.com/view/olaparib-bolsters-lutetium-lu-177-vipivotide-tetraxetan-activity-in-mcrpc

ONCLIVE
11 Jul 2023

https://www.businesswire.com/news/home/20230603005010/en

BUSINESSWIRE
03 Jun 2023

https://www.fiercepharma.com/pharma/astrazeneca-mercks-lynparza-wins-fda-nod-prostate-cancer-subgroup-following-advisory

Zoey Becker FIERCE PHARMA
02 Jun 2023

https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration#:~:text=On%20May%2031%2C%202023%2C%20the,mCRPC)%2C%20as%20determined%20by%20an

FDA
01 Jun 2023

https://www.businesswire.com/news/home/20230601005453/en

BUSINESSWIRE
01 Jun 2023

https://www.clinicaltrialsarena.com/news/astrazeneca-positive-endometrial-cancer-therapy/

CLINICAL TRIALS ARENA
30 May 2023

https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-lynparza-prolonged-pfs-in-endometrial-cancer.html

PRESS RELEASE
26 May 2023

https://news.cision.com/astrazeneca/r/imfinzi-plus-lynparza-and-imfinzi-alone-both-significantly-improved-progression-free-survival-in-adv,c3775242

ENDPTS
26 May 2023

https://www.business-standard.com/world-news/us-fda-panel-backs-restricted-use-of-astrazeneca-s-prostate-cancer-drug-123050100632_1.html

BUSINESS-STANDARD
02 May 2023

https://www.fiercepharma.com/pharma/astrazeneca-lynparza-combo-fda-advisory-committee-prostate-cancer-vote

Angus Liu FIERCE PHARMA
29 Apr 2023

https://www.businesswire.com/news/home/20230428005574/en

BUSINESSWIRE
28 Apr 2023

https://endpts.com/fda-raises-concerns-about-plan-to-expand-lynparza-use-ahead-of-adcomm/

Katherine Lewin ENDPTS
27 Apr 2023

https://www.fiercebiotech.com/biotech/trailing-astrazeneca-and-merck-junshi-reports-phase-3-ovarian-cancer-success-lynparza-rival

Nick Paul Taylor FIERCE BIOTECH
13 Apr 2023

https://www.thepharmaletter.com/article/nice-s-recommendation-on-lynparza-labelled-an-amazing-moment

THE PHARMA LETTER
07 Apr 2023

https://www.fiercepharma.com/pharma/astrazeneca-face-tough-fda-scrutiny-imfinzi-lynparza-ovarian-cancer-analyst

FIERCE PHARMA
06 Apr 2023

https://www.europeanpharmaceuticalreview.com/news/180797/mhra-approves-prostate-cancer-combination-therapy/

EUROPEAN PHARMACEUTICAL REVIEW
21 Mar 2023

https://www.pharmatimes.com/news/astrazeneca_and_msds_lynparza_gets_green_light_1489951

PHARMATIMES
20 Mar 2023

https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-panel-review-expanded-use-merck-astrazenecas-cancer-drug-2023-03-02/

REUTERS
03 Mar 2023

https://www.astrazeneca.com/media-centre/press-releases/2023/overall-survival-analysis-of-the-lynparza-propel-phase-iii-trial-in-metastatic-castration-resistant-prostate-cancer.html

PRESS RELEASE
17 Feb 2023

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/natco-pharma-submits-application-with-usfda-for-generic-cancer-drug/articleshow/97864876.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

ECONOMIC TIMES
13 Feb 2023

https://www.biopharmadive.com/news/lynparza-eu-approval-prostate-cancer-fda-parp/639298/

Ben Fidler BIOPHARMADIVE
22